Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

A new company is making its debut with a series A sum that’s sure to make hearts race. | A new company is making its debut ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team with proven ability to develop therapies for CNS ...

Guggenheim Securities announced today that Jami Rubin will join the firm’s healthcare investment banking practice as a Senior Managing DirectorNEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Guggenheim ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Stanton Williams has been selected to design the Fleming Centre, a state-of-the-art research and public engagement facility ...

In a release issued under the same headline earlier today by HPQ Silicon Inc. , please note that in the 11th paragraph, the number of units issued is not 1,009,343 but 1,083,333. The revised release ...

This year's 10 most-read Chicago Inno stories were dominated by new developments and recent funding rounds, along with one ...